Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,106

Employees15,106

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,106

Employees15,106

REGN Key Statistics

Market cap

62.66B

Market cap62.66B

Price-Earnings ratio

15.07

Price-Earnings ratio15.07

Dividend yield

0.29%

Dividend yield0.29%

Average volume

1.00M

Average volume1.00M

High today

$610.43

High today$610.43

Low today

$590.17

Low today$590.17

Open price

$602.35

Open price$602.35

Volume

850.91K

Volume850.91K

52 Week high

$1,211.20

52 Week high$1,211.20

52 Week low

$476.49

52 Week low$476.49

REGN News

TipRanks 2h

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Elevate Your In...

TipRanks 2h

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?

Regeneron Pharmaceuticals ((REGN)), Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Tak...

TipRanks 1d

Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: A Closer Look

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

Analyst ratings

75%

of 28 ratings

Buy

75%

Hold

21.4%

Sell

3.6%

More REGN News

TipRanks 2d

Regeneron’s PNH Study: Long-Term Safety and Efficacy of Pozelimab + Cemdisiran

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

TipRanks 2d

Regeneron says FDA delayed review of two Eylea HD submissions

Regeneron (REGN) Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea HD injection r...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.